****

**11 November 2019**

**SCOTTISH MEDICINES CONSORTIUM RECOMMENDS ELMIRON®
FOR THE TREATMENT OF BLADDER PAIN SYNDROME**

Consilient Health welcomes the decision by the Scottish Medicines Consortium (SMC) to recommend elmiron**®** (pentosan polysulfate sodium) for bladder pain syndrome (BPS) within its marketing authorisation1. elmiron**®** is the only licensed oral medication for BPS with glomerulations or Hunner’s lesions (referred to as interstitial cystitis/BPS)2,3.

SMC is the national source of advice on the clinical and cost-effectiveness of all new medicines for NHSScotland. Its recommendation came after Consilient Health agreed a Patient Access Scheme with the SMC which will make elmiron**®** available to NHSScotland.

Mr Thomas Lam, Consultant Urological Surgeon and Honorary Senior Clinical Lecturer, Aberdeen Royal Infirmary and Academic Urology Unit, University of Aberdeen said: “I’m pleased that the SMC has approved the use of elmiron**®**. BPS is challenging to manage and difficult to treat; there is no standard treatment and a range of treatment options is crucial. elmiron**®** is an effective and well-tolerated medicine in BPS, and its approval will benefit patients by increasing the available treatment options.”

Susannah Fraser, Communication and Media Manager, Bladder Health UK said: “BPS is a debilitating condition and has a considerable detrimental impact on the individual’s lifestyle, ability to work, emotional health and relationships. Their quality of life is hugely compromised. For individuals in Scotland to be able to access elmiron**®** on the NHS is really good news.”

Amanda Paxon, Consilient Health UK Country Manager Pharmaceuticals said: “This is a condition with a significant unmet clinical need and the company is delighted that elmiron**®** has been recommended for the treatment of IC/BPS”.

 **ENDS**

**Notes to editor**

Interstitial cystitis (IC)/bladder pain syndrome (BPS)4,5
BPS is a condition defined as chronic (i.e. more than six months) pelvic pain, pressure or discomfort perceived to be related to the bladder and accompanied by at least one other urinary symptom e.g. urinary urgency or frequency. A subset of individuals with BPS have lesions on the inside of the bladder wall, either glomerulations or Hunner’s lesions and this is referred to as IC/BPS. Approximately 90% of individuals with IC/BPS are women, and the condition has a considerable detrimental impact on the individual’s lifestyle, work, emotional health and relationships. Their quality of life is hugely compromised.

elmiron**®** (pentosan polysulfate sodium)2,6,7
elmiron**®** is a medicine that contains the active substance pentosan polysulfate sodium. After taking the medicine it passes into the urine and attaches to the lining of the bladder, helping to form a protective layer6. elmiron**®** is licensed for the treatment of BPS characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition. elmiron**®** improves the pain, urgency to urinate, need to urinate more often and gives patients an improved quality of life2.

elmiron**®** is thought to work by restoring a damaged, thin, or ‘leaky’ bladder surface. This surface (glycosaminoglycans or GAG layer) has a coating of mucus which protects the bladder wall from bacteria and irritating substances in urine. It is believed that elmiron**®** functions as a synthetic GAG layer, but its exact mechanism of action in IC/BPS is unclear7.

Consilient Health
Established in 2005 with headquarters in Ireland, Consilient Health is an independent, dynamic and rapidly growing pharmaceutical company with a rich heritage of commercialising products in complex markets in therapeutic areas such as women’s health, urology and endocrinology. The company has a strategy of partnering with innovative companies to bring medicines to market that serve a clear unmet clinical need. In 2018 Consilient Health signed a long-term exclusive distribution agreement with bene-Arzneimittel GmbH to distribute elmiron**®** in the UK.

**References**1. Scottish Medicines Consortium November 2019. <https://www.scottishmedicines.org.uk/about-us/latest-updates/> (accessed November 2019).
2. bene-Arzneimittel GmbH. elmiron**®** (pentosan polysulfate sodium) 100 mg hard capsules Summary of Product Characteristics. July 2019.

3. Committee for Medicinal Products for Human Use (CHMP) Assessment report elmiron**®** EMA/287422/2017 23 March 2016. http://www.ema.europa.eu/docs/en\_GB/document\_library/EPAR\_-Public\_assessment\_report/human/004246/WC500229392.pdf

4. National Institute for Health Research. Pentosan polysulfate sodium (elmiron**®**) for bladder pain syndrome (interstitial cystitis) NIHRIO (HSRIC) ID: 13742 NICE ID: 9517 <http://www.io.nihr.ac.uk/wp-content/uploads/migrated_new/13742-Pentosan.pdf> (accessed July 2019).
5. National Health Service. Interstitial cystitis. <https://www.nhs.uk/conditions/interstitial-cystitis/> (accessed July 2019).
6. bene-Arzneimittel GmbH. elmiron**®** (pentosan polysulfate sodium) 100 mg hard capsules Patient Information Leaflet. July 2019

7. Interstitial Cystitis Association website <https://www.ichelp.org/diagnosis-treatment/treatments/pentosan-polysulfate-sodium> (accessed September 2019).

 **For further information, please contact:**Louise Blakeborough, Chapter Five T: +44(0)7831 444789

UK-ELM-58 October 2019